GLP-1 Medications: Myths, Safety, and New Developments

Multiple articles address GLP-1 drugs (Ozempic, Wegovy) including myth-busting, potential to stop insulin, oral pill options, compounded versions under FDA scrutiny, and policy impacts. Today, FDA approved oral semaglutide for chronic weight management, a pill alternative with 16.6% weight loss and $149/month self-pay price. A new study on insurance denials shows high rejection rates for GLP-1s. This is a rapidly evolving area with significant implications for diabetes and weight management.